Kailera Therapeutics
Waltham, Massachusetts, United States · Biotechnology, Health Care · 138 employees
Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive clinical trial results in obesity in China. The Company is also advancin
Funding history
- Series series b — $600.0M — Oct 2025
- Series series a — $400.0M — Oct 2024
Recent signals
- Apr 20, 2026: SEC 8-K (5.03): On April 20, 2026, Kailera Therapeutics, Inc. filed an amended and restated certificate of incorporation with the Secretary of State of Delaware in connection with the closing of its initial public offering (IPO). This Restated Certificate, approved by the Company's board of directors and stockholders, sets the authorized number of shares of common stock at 800,000,000 and eliminates all references to the previously existing series of preferred stock while authorizing 10,000,000 shares of undesignated preferred stock. The strategic implications include provisions for future equity financing and adjustments to the capital structure following the IPO.
- Jan 05, 2026: Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer
- Oct 14, 2025: Raised $600.0M in Series series b
- Nov 12, 2024: Kailera Therapeutics Names Scott M. Akamine as Chief Legal Officer
- Oct 01, 2024: Raised $400.0M in Series series a
See plans & pricing → Track Kailera Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.